查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947953

Eculizumab市場依適應症、通路、最終用戶及病患年齡層別分類，全球預測，2026-2032年

Eculizumab Market by Indication, Distribution Channel, End User, Patient Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，Eculizumab市場價值將達到 43.5 億美元，到 2026 年將成長至 45.3 億美元，複合年成長率為 5.19%，到 2032 年將達到 62.1 億美元。

關鍵市場統計數據
基準年 2025 43.5億美元
預計年份：2026年 45.3億美元
預測年份 2032 62.1億美元
複合年成長率 (%) 5.19%

關於Eculizumab在複雜補體依賴性疾病中不斷演變的作用的執行性引言

Eculizumab已成為補體介導疾病領域的生物製藥，本概要概述了其臨床意義、商業性趨勢和策略轉折點。本文重點闡述了其作為末端補體（C5）抑制劑的作用機制，並著重介紹了其臨床應用如何從血液學擴展到神經學，從而形成超越傳統專科界限的新型應用模式。理解這一背景將有助於相關人員更清晰地理解該藥物在複雜疾病治療中的重要性，並解讀後續分析。

對推動Eculizumab治療領域快速變革的科學、監管與競爭因素進行深入分析

近期科學進展、治療選擇的多樣化以及監管環境的變化如何重塑Eculizumab的競爭格局和臨床格局

由於科學創新、競爭對手的湧入以及監管環境的不斷變化，Eculizumab的市場環境正在經歷變革性變化。補體生物學的進展、長效C5抑制劑以及針對近端補體成分的藥物的出現，正在改變臨床決策，帶來不同的給藥頻率、給藥途徑和安全性特徵。因此，臨床醫師在選擇治療慢性補體依賴性疾病的方案時，會更謹慎地權衡治療效益與治療負擔。

評估美國計劃於 2025 年實施的關稅政策變化對高價值生物製藥的價值鏈、生產製造和患者獲取途徑的累積影響

新增或提高關稅可能會對整個生物製藥價值鏈產生連鎖反應，影響原料採購、契約製造成本以及Eculizumab等治療藥物的物流。關稅導致的成本上漲通常首先表現為活性藥物成分和特殊耗材採購成本的增加，迫使製造商重新評估其供應基礎並考慮近岸外包策略。隨著時間的推移，這些壓力可能導致製造商加速投資國內生產能力，並採取合約避險策略來穩定投入成本。

整合適應症、通路、終端用戶和患者群體特徵等趨勢的策略性細分洞察，有助於制定有針對性的商業策略。

Eculizumab市場涵蓋多種適應症，每種適應症都有其獨特的臨床路徑和治療模式。非典型溶血性尿毒症候群 (aHUS) 的治療分為第一線和第二線治療，早期療育和難治性病例需要不同的診斷流程和支持。重症肌無力和視神經脊髓炎頻譜障礙均存在不可治療和難治性亞組，通常需要具有神經科專業知識的醫師進行細緻的臨床判斷。陣發性睡眠性血尿症也同樣分為第一線和二線治療組，既往輸血史和血栓風險會影響治療的緊迫性和監測頻率。

影響市場准入、監管合規性和商業性可行性的區域優先事項和差異化策略（美洲、歐洲、中東和非洲、亞太地區）

區域趨勢對Eculizumab療法的應用有顯著影響，不同的法規結構、報銷機制和醫療基礎設施都會影響其普及程度。在美洲，強調罕見疾病治療可及性的政策和完善的專科醫療網路鼓勵在三級醫療中心集中使用依庫珠單抗，而支付方談判和批量採購協議則決定了其商業性條款。同時，歐洲、中東和非洲（EMEA）地區的法規環境各不相同，包括各國不同的衛生技術評估（HTA）流程、報銷機構和醫院容量。因此，確保依庫珠單抗被納入藥品目錄需要量身定做的實證依據和彈性價格設定策略。

公司定位、夥伴關係策略和生命週期管理方法塑造了Eculizumab及相關補體標標靶治療的競爭格局。

主要企業的策略體現了雙重重點：既要保護現有業務，又要投資下一代資產和策略合作。藥物研發公司致力於透過拓展適應症、進行病患支援專案和進行長期安全性研究來延長藥物生命週期，從而提升臨床價值，同時利用其生產規模和全球分銷網路來維持供應的可靠性。同時，致力於研發其他補體路徑標靶或長效C5抑制劑的公司則採取了互補策略，包括共同開發契約、授權協議以及針對特定未滿足醫療需求族群的標靶臨床項目。

為產業領導者提供切實可行的建議，以保障補充療法領域的市場准入、最佳化商業性績效並加速以病人為中心的創新

產業領導者應優先考慮三大支柱：拓展臨床證據、增強供應鏈韌性、與支付者共用價值。首先，投資於有針對性的真實世界證據項目，以證明關鍵適應症和亞群的功能性療效。這些證據將有助於加強報銷談判和臨床應用，尤其是在出現療效比較問題時。其次，透過原料供應商多元化、探索本地製造夥伴關係關係以及實施庫存策略來降低供應鏈風險，從而減少關稅和物流中斷的影響。這些營運措施將確保醫院和專科診所的持續服務。

採用嚴謹的混合調查方法，結合關鍵相關人員的訪談、二手證據的綜合分析、背景政策分析，得出可靠的結論。

本研究採用混合方法，結合結構化的初步研究、全面的二手研究、情境化的監管審查。初步研究包括對血液科和神經科專家、醫院藥屋主任、專科診所主任和支付方進行深度訪談，以了解實際治療路徑、就醫障礙和通路偏好。這些訪談，以及與供應鏈和生產專家的討論，幫助我們了解了物流、低溫運輸要求和產能限制。

審查報告重點強調了維持補體抑制劑治療患者臨床可近性和長期價值的策略重點。

總之，Eculizumab在快速發展的治療領域中仍然是一種重要的臨床治療方法，該領域的特點是科學創新、監管預期變化和競爭日益激烈。新進入者的出現、替代性補體標靶機制的出現以及支付方期望的轉變，都要求我們採取積極主動、基於實證醫學的生命週期管理方法。那些能夠將可靠的真實世界證據生成、強大的生產能力和以地域為導向的策略相結合的公司，將更有利於維持藥物的可及性，並向支付方和醫療服務提供方證明其長期價值。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章Eculizumab市場依適應症分類

  • 非典型溶血性尿毒症候群
    • 一線治療
    • 二級治療
  • 全身型重症肌無力
    • 不人道
    • 耐火
  • 視神經脊髓炎頻譜障礙
    • 不人道
    • 耐火
  • 陣發性睡眠性血尿症
    • 一線治療
    • 二級治療

第9章 按通路分類的Eculizumab市場

  • 線上
  • 離線

第10章 依最終用戶分類的Eculizumab市場

  • 醫院
    • 二級醫療機構
    • 三級醫療機構
  • 專科診所
    • 血液科診所
    • 神經內科診所

第11章 依病患年齡層別分類的Eculizumab市場

  • 成人版
  • 兒童
  • 老年人

第12章 依Eculizumab市場區域分類

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章Eculizumab市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章Eculizumab市場（依國家分類）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國Eculizumab市場

第16章：中國Eculizumab市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Apellis Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Catalyst Biosciences, Inc.
  • Celltrion Inc.
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Samsung Bioepis Co., Ltd.
  • Sanofi SA
  • Swedish Orphan Biovitrum AB
  • UCB SA
Product Code: MRR-4F7A6D4FB6A3

The Eculizumab Market was valued at USD 4.35 billion in 2025 and is projected to grow to USD 4.53 billion in 2026, with a CAGR of 5.19%, reaching USD 6.21 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.35 billion
Estimated Year [2026] USD 4.53 billion
Forecast Year [2032] USD 6.21 billion
CAGR (%) 5.19%

Executive introduction to eculizumab's evolving role across complex complement-mediated disorders

Eculizumab has emerged as a defining biologic for complement-mediated conditions, and this executive introduction frames its clinical relevance, commercial dynamics, and strategic inflection points. The narrative highlights the therapy's mechanism as a terminal complement (C5) inhibitor and underscores how its clinical applications have expanded beyond hematology into neurology, creating new patterns of usage that cross traditional specialty boundaries. This context prepares stakeholders to interpret subsequent analyses with a clear understanding of the therapeutic's centrality to complex disease management.

Moreover, the introduction situates eculizumab within a larger ecosystem of next-generation complement inhibitors, long-acting formulations, and alternative complement-pathway approaches. It explains how these innovations interact with patient access pathways, hospital treatment protocols, and specialty clinic workflows. By presenting clinical developments alongside supply chain and reimbursement considerations, the introduction equips readers to appreciate downstream implications for clinical trial design, market access strategy, and manufacturing scale-up.

Finally, the introduction sets an analytical tone focused on practical implications rather than speculative forecasts. It emphasizes evidence-based evaluation of indications, distribution channels, and end-user behavior, thereby enabling executives to prioritize near-term actions and longer-term strategic pivots with confidence.

An in-depth view of scientific, regulatory, and competitive forces driving rapid transformation in the eculizumab treatment ecosystem

How recent scientific advances, treatment alternatives, and regulatory shifts are reshaping the competitive and clinical landscape for eculizumab

The landscape around eculizumab is undergoing transformative shifts driven by scientific innovation, competitive entrants, and evolving regulatory approaches. Advances in complement biology and the emergence of long-acting C5 inhibitors, along with agents targeting proximal complement components, are altering clinical decision-making by offering differentiated dosing frequency, administration setting, and safety profiles. As a result, clinicians increasingly weigh efficacy against treatment burden when selecting therapies for chronic complement-driven diseases.

In parallel, regulatory authorities have signaled greater openness to expedited pathways for therapies that address high unmet need, while also tightening post-approval surveillance expectations for rare disease indications. These regulatory dynamics have encouraged sponsors to pursue label expansions and real-world evidence programs that demonstrate long-term safety and functional outcomes. Simultaneously, payer scrutiny has intensified, prompting manufacturers to invest in value-based contracting and patient support infrastructures to sustain access.

Consequently, the competitive environment is shifting from a single-product focus to portfolio-level strategies that integrate clinical data, lifecycle management, and patient-centric services. This shift compels incumbent players to adapt commercial models, optimize channel strategies, and deepen engagement with specialty clinics and multidisciplinary care teams to retain clinical preference and payer support.

Evaluating the projected cumulative effects of United States tariff policy changes in 2025 on supply chain, manufacturing, and patient access for high-value biologics

The imposition of new or increased tariffs can ripple through the biologics value chain, affecting raw material sourcing, contract manufacturing costs, and logistics for therapies like eculizumab. Tariff-driven cost increases tend to manifest initially in higher procurement expenses for active pharmaceutical ingredients and specialized consumables, leading manufacturers to reassess supplier basins and near-shoring strategies. Over time, these pressures can accelerate investments in domestic manufacturing capacity or contractual hedges to stabilize input costs.

In addition, tariffs influence distribution economics by increasing landed costs of finished products and adding complexity to cross-border movement. Hospitals and specialty clinics may experience incremental administrative burdens as providers reconcile changes to procurement contracts and inventory management practices. Meanwhile, payers and health systems could intensify cost-containment efforts, potentially heightening demands for outcome-linked pricing arrangements or step-therapy policies that favor lower-cost alternatives when clinically appropriate.

Therefore, stakeholders should anticipate a period of operational recalibration in response to tariff-driven cost pressures. Manufacturers will likely explore supply chain de-risking, pricing adjustments in negotiated channels, and strengthened patient assistance programs to mitigate access disruption. Ultimately, the cumulative tariff impact will be mediated by contractual flexibility, manufacturing footprint, and the ability to demonstrate compelling clinical value that justifies continued access despite increased system costs.

Strategic segmentation insights synthesizing indication, distribution channel, end user, and patient age group dynamics to inform targeted commercial strategies

The market for eculizumab spans multiple indications, each with distinct clinical pathways and treatment paradigms. Atypical Hemolytic Uremic Syndrome is managed across first-line and second-line settings where early intervention versus refractory scenarios dictate different diagnostic workflows and support needs. Generalized Myasthenia Gravis and Neuromyelitis Optica Spectrum Disorder each present non-refractory and refractory subpopulations that require nuanced clinical decision-making, often involving neurologists with subspecialty expertise. Paroxysmal Nocturnal Hemoglobinuria similarly divides into first-line and second-line cohorts, where prior transfusion history and thrombotic risk shape treatment urgency and monitoring frequency.

Distribution channels further differentiate access and administration models, with hospital pharmacies-operating in secondary and tertiary hospitals-supporting inpatient and complex infusion scheduling, while retail pharmacies, comprising chain and independent outlets, play a role in outpatient dispensing, home infusion coordination, and patient education. End users reflect this channel complexity: hospitals and specialty clinics each have subgroups with specialized infrastructure, whereby secondary and tertiary hospitals manage acute, multi-disciplinary cases and hematology or neurology specialty clinics provide longitudinal care, infusion services, and adherence support.

Patient age group segmentation adds another layer of operational consideration. Adult patients split into 19-65 and over-65 cohorts, with geriatric patients often presenting comorbidities that affect dosing considerations and safety monitoring, whereas pediatric populations-adolescent and neonatal-require tailored formulations, weight-based dosing, and specialized caregiver support. Integrating these segmentation dimensions enables more precise targeting of clinical education, patient support services, channel optimization, and pricing strategies in order to align resources with the pathways that most influence uptake and sustained treatment.

Regional priorities and differentiated strategies across Americas, Europe, Middle East & Africa, and Asia-Pacific that shape access, regulatory engagement, and commercial execution

Regional dynamics exert a major influence on the diffusion of eculizumab therapies, with distinct regulatory frameworks, reimbursement mechanisms, and healthcare infrastructure shaping uptake. In the Americas, policy emphasis on rare disease access and established specialty care networks often facilitates concentrated use in tertiary centers, while payer negotiations and bundled purchasing arrangements shape commercial terms. Conversely, Europe, Middle East & Africa presents a diverse regulatory mosaic where country-level HTA processes, national reimbursement bodies, and variable hospital capabilities require tailored evidence dossiers and flexible pricing approaches to secure formulary placement.

In the Asia-Pacific region, rapid growth in specialty care capacity in urban centers contrasts with capacity constraints in rural areas, prompting manufacturers to prioritize partnerships with center-of-excellence sites and to invest in clinician education and diagnostic capability-building. Across all regions, evolving real-world evidence expectations and localized post-marketing surveillance influence launch sequencing and the design of observational studies intended to support reimbursement dossiers. Furthermore, regional supply chain resilience and local manufacturing policy considerations increasingly inform decisions about production siting and inventory strategies.

Consequently, manufacturers and service providers must adopt differentiated regional playbooks that combine regulatory intelligence, targeted clinical evidence generation, and nuanced payer engagement to navigate heterogeneous market access landscapes and to ensure consistent patient access across global regions.

Corporate positioning, partnership strategies, and lifecycle management approaches shaping competitive dynamics for eculizumab and adjacent complement-targeting therapies

Key company strategies reflect a dual focus on protecting incumbent franchises while investing in next-generation assets and strategic partnerships. The original innovator has concentrated on lifecycle extensions through label expansions, patient support programs, and long-term safety studies that reinforce clinical value, while also leveraging manufacturing scale and global distribution networks to maintain supply reliability. At the same time, a wave of companies pursuing alternative complement pathway targets and longer-acting C5 inhibitors have adopted complementary approaches, including co-development agreements, licensing deals, and targeted clinical programs focusing on subpopulations with high unmet need.

Partnerships with contract manufacturing organizations, logistics providers, and clinical centers of excellence are common as companies seek to optimize cold-chain integrity, reduce lead times, and strengthen post-marketing evidence collection. Additionally, corporate strategies increasingly emphasize integrated service offerings-linking therapy delivery with diagnostics, adherence monitoring, and outcomes tracking-to differentiate value propositions for payers and providers. Intellectual property timelines and biosimilar entrants further influence commercial tactics, prompting incumbent firms to reinforce brand value through real-world outcome data, specialized training for prescribers, and bundled care solutions that address total cost of care considerations.

These strategic moves collectively shape a landscape in which clinical differentiation, service integration, and manufacturing resilience determine competitive advantage more than product exclusivity alone.

Actionable recommendations for industry leaders to protect access, optimize commercial performance, and accelerate patient-centric innovation in complement therapeutics

Industry leaders should prioritize a three-pronged approach that combines clinical evidence expansion, supply chain resilience, and payer-aligned value communication. First, invest in targeted real-world evidence programs that document functional outcomes across key indications and subpopulations; this evidence will strengthen reimbursement negotiations and clinical adoption, particularly where comparative effectiveness questions arise. Second, de-risk supply chains by diversifying raw material suppliers, exploring localized manufacturing partnerships, and implementing inventory strategies that reduce vulnerability to tariff- or logistics-induced disruptions. These operational moves will preserve continuous access for hospitals and specialty clinics.

Third, develop payer-centric value propositions that extend beyond pricing to include outcomes-based contracts, patient support services, and adherence programs that demonstrably reduce long-term health system costs. In parallel, refine segmentation-based commercial tactics that match channel capabilities with patient needs, ensuring tertiary centers, specialty clinics, and outpatient infusion settings each receive tailored training and support. Finally, leaders should pursue collaborative initiatives with clinical networks to standardize diagnostic pathways and care algorithms, thereby reducing time-to-diagnosis and ensuring appropriate targeting of high-value therapies.

Taken together, these recommendations enable organizations to protect clinical access, sustain commercial performance, and accelerate innovations that deliver measurable benefits for patients and health systems.

Rigorous mixed-method research methodology integrating primary stakeholder interviews, secondary evidence synthesis, and contextual policy analysis to support robust conclusions

This study employs a mixed-methods approach combining structured primary research with comprehensive secondary analysis and contextual regulatory review. Primary research involved in-depth interviews with clinicians across hematology and neurology specialties, hospital pharmacy directors, specialty clinic leaders, and payers to capture real-world treatment pathways, access barriers, and channel preferences. These interviews were complemented by discussions with supply chain and manufacturing experts to understand logistics, cold-chain requirements, and capacity constraints.

Secondary evidence synthesis included peer-reviewed clinical literature, public regulatory documents, prescribing guidelines, and published safety and efficacy reports to create a validated clinical foundation for the analysis. The research team triangulated findings across sources to identify consistent themes and to highlight areas of divergence that warrant further investigation. Finally, policy and tariff analyses were conducted using official trade and regulatory publications, combined with scenario-based modeling of operational impacts to inform actionable recommendations. Quality assurance measures included expert review cycles and cross-functional validation to ensure the analysis reflects both clinical realities and commercial imperatives.

Concluding synthesis emphasizing strategic priorities for sustaining clinical access and long-term value for patients receiving complement inhibition therapies

In conclusion, eculizumab remains a clinically important therapy within a rapidly evolving therapeutic class characterized by scientific innovation, changing regulatory expectations, and competitive diversification. The confluence of new entrants, alternative complement-targeting mechanisms, and evolving payer expectations requires a proactive, evidence-driven approach to lifecycle management. Companies that combine robust real-world evidence generation with resilient manufacturing and tailored regional strategies will be best positioned to sustain access and justify long-term value to payers and providers.

Furthermore, operational responsiveness to supply chain pressures-including tariff-related cost shifts-will be critical to maintaining uninterrupted access for patients treated across hospitals and specialty clinics. Strategic investments in patient support, outcomes tracking, and collaborative care pathways can mitigate access risk while reinforcing clinical value. Ultimately, the most successful players will be those that integrate clinical differentiation with pragmatic commercial tactics, ensuring therapies reach the patients who will benefit most while aligning with system-level priorities for affordability and measurable outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Eculizumab Market, by Indication

  • 8.1. Atypical Hemolytic Uremic Syndrome
    • 8.1.1. First Line
    • 8.1.2. Second Line
  • 8.2. Generalized Myasthenia Gravis
    • 8.2.1. Non-Refractory
    • 8.2.2. Refractory
  • 8.3. Neuromyelitis Optica Spectrum Disorder
    • 8.3.1. Non-Refractory
    • 8.3.2. Refractory
  • 8.4. Paroxysmal Nocturnal Hemoglobinuria
    • 8.4.1. First Line
    • 8.4.2. Second Line

9. Eculizumab Market, by Distribution Channel

  • 9.1. Online
  • 9.2. Offline

10. Eculizumab Market, by End User

  • 10.1. Hospitals
    • 10.1.1. Secondary Hospitals
    • 10.1.2. Tertiary Hospitals
  • 10.2. Specialty Clinics
    • 10.2.1. Hematology Clinics
    • 10.2.2. Neurology Clinics

11. Eculizumab Market, by Patient Age Group

  • 11.1. Adult
  • 11.2. Pediatric
  • 11.3. Geriatric

12. Eculizumab Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Eculizumab Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Eculizumab Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Eculizumab Market

16. China Eculizumab Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Alexion Pharmaceuticals, Inc.
  • 17.7. Amgen Inc.
  • 17.8. Apellis Pharmaceuticals, Inc.
  • 17.9. AstraZeneca PLC
  • 17.10. Biogen Inc.
  • 17.11. Boehringer Ingelheim International GmbH
  • 17.12. Bristol Myers Squibb Company
  • 17.13. Catalyst Biosciences, Inc.
  • 17.14. Celltrion Inc.
  • 17.15. Janssen Pharmaceuticals, Inc.
  • 17.16. Merck & Co., Inc.
  • 17.17. Novartis AG
  • 17.18. Pfizer Inc.
  • 17.19. Regeneron Pharmaceuticals, Inc.
  • 17.20. Roche Holding AG
  • 17.21. Samsung Bioepis Co., Ltd.
  • 17.22. Sanofi SA
  • 17.23. Swedish Orphan Biovitrum AB
  • 17.24. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ECULIZUMAB MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ECULIZUMAB MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ECULIZUMAB MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ECULIZUMAB MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ECULIZUMAB MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ECULIZUMAB MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ECULIZUMAB MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ECULIZUMAB MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ECULIZUMAB MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ECULIZUMAB MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ECULIZUMAB MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ECULIZUMAB MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ECULIZUMAB MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ECULIZUMAB MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ECULIZUMAB MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ECULIZUMAB MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ECULIZUMAB MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ECULIZUMAB MARKET SIZE, BY NON-REFRACTORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ECULIZUMAB MARKET SIZE, BY NON-REFRACTORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ECULIZUMAB MARKET SIZE, BY NON-REFRACTORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ECULIZUMAB MARKET SIZE, BY REFRACTORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ECULIZUMAB MARKET SIZE, BY REFRACTORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ECULIZUMAB MARKET SIZE, BY REFRACTORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ECULIZUMAB MARKET SIZE, BY NON-REFRACTORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ECULIZUMAB MARKET SIZE, BY NON-REFRACTORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ECULIZUMAB MARKET SIZE, BY NON-REFRACTORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ECULIZUMAB MARKET SIZE, BY REFRACTORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ECULIZUMAB MARKET SIZE, BY REFRACTORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ECULIZUMAB MARKET SIZE, BY REFRACTORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ECULIZUMAB MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ECULIZUMAB MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ECULIZUMAB MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ECULIZUMAB MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ECULIZUMAB MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ECULIZUMAB MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ECULIZUMAB MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ECULIZUMAB MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ECULIZUMAB MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ECULIZUMAB MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ECULIZUMAB MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ECULIZUMAB MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ECULIZUMAB MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ECULIZUMAB MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ECULIZUMAB MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ECULIZUMAB MARKET SIZE, BY SECONDARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ECULIZUMAB MARKET SIZE, BY SECONDARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ECULIZUMAB MARKET SIZE, BY SECONDARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ECULIZUMAB MARKET SIZE, BY TERTIARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ECULIZUMAB MARKET SIZE, BY TERTIARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ECULIZUMAB MARKET SIZE, BY TERTIARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ECULIZUMAB MARKET SIZE, BY HEMATOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ECULIZUMAB MARKET SIZE, BY HEMATOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ECULIZUMAB MARKET SIZE, BY HEMATOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ECULIZUMAB MARKET SIZE, BY NEUROLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ECULIZUMAB MARKET SIZE, BY NEUROLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ECULIZUMAB MARKET SIZE, BY NEUROLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ECULIZUMAB MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ECULIZUMAB MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ECULIZUMAB MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ECULIZUMAB MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ECULIZUMAB MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ECULIZUMAB MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ECULIZUMAB MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ECULIZUMAB MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ECULIZUMAB MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ECULIZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ECULIZUMAB MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ECULIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA ECULIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE ECULIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST ECULIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA ECULIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC ECULIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL ECULIZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN ECULIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GCC ECULIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GCC ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 184. GCC ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 185. GCC ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 186. GCC ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 187. GCC ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 188. GCC ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. GCC ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. GCC ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 191. GCC ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 192. GCC ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION ECULIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS ECULIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. G7 ECULIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. G7 ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. G7 ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 218. G7 ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 219. G7 ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 220. G7 ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 221. G7 ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. G7 ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. G7 ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 224. G7 ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 225. G7 ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 226. NATO ECULIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. NATO ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 228. NATO ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 229. NATO ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 230. NATO ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 231. NATO ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 232. NATO ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. NATO ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. NATO ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 235. NATO ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 236. NATO ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL ECULIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES ECULIZUMAB MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA ECULIZUMAB MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA ECULIZUMAB MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA ECULIZUMAB MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA ECULIZUMAB MARKET SIZE, BY GENERALIZED MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA ECULIZUMAB MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA ECULIZUMAB MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA ECULIZUMAB MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA ECULIZUMAB MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA ECULIZUMAB MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA ECULIZUMAB MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA ECULIZUMAB MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)